This site is intended for healthcare professionals

More than a dozen studies of Ocrevus for multiple sclerosis presented at ECTRIMS.

Read time: 1 mins
Last updated:8th Oct 2021
Published:6th Oct 2021
Genentech/Roche announced that new Ocrevus (ocrelizumab) data will be presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from October 13 – 15, 2021.

These data include abstracts highlighting new longer-term efficacy and safety for Ocrevus as well as ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS.

Ocrevus data also shows sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5 years for relapsing MS (RMS). In addition, long-term safety analysis of all clinical trials will reinforce the consistently favorable benefit-risk profile of Ocrevus. A subgroup analysis of three studies (SaROD, CHORDS and ENSEMBLE PLUS) in Black, African-American, Hispanic and Latino populations treated with a 2-hour Ocrevus infusion will be presented.

Abstracts include: "Sustained Reduction in 48-week Confirmed Disability Progression in Patients with PPMS Treated with Ocrelizumab in the ORATORIO OLE: 8-Year Follow-up", "Long-term Reduction of Relapse Rate and Confirmed Disability Progression After 7.5 Years of Ocrelizumab Treatment in Patients with Relapsing Multiple Sclerosis in the OPERA OLE" and "Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis".

Condition: Multiple Sclerosis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights